Список литературы

1. Korgavkar K., Xiong M., Weinstock M. Changing incidence trends of cutaneous Tcell lymphoma. JAMA Dermatol. 2013; 149(11): 1295 - 1299.

2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneouslymphomas. Blood. 2005; 105(10): 3768 - 3785.

3. Keehn C.A., Belongie I.P., Shistik G. et al. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007; 14(2): 102 - 111.

4. Cerroni L.Mycosis fungoides - clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 2 - 10.

5. Willemze R.Mycosis fungoides variants - clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 11 - 17.

6. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Sosiety for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110: 1713 - 1722

7. Horwitz S.M., Olsen E.A., Duvic M. et al. Review of the treatment of mycosis fungoides and syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008; 6(4): 436 - 442.

8. Delfau-Larue M.H., Laroche L., WechslerJ. et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 2000; 96(9): 2987 - 2992.

9. Ponti R., Quaglino P., Novelli M. et al. T-cell receptor gamma gene rearrangement bymultiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneousT-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatorydisease: correlation with clinical, histological and immunophenotypical findings.Br J Dermatol. 2005; 153(3): 565 - 573.

10. Kirsch I.R., Watanabe R., O'Malley J.T. et al. TCR sequencing facilitates diagnosisand identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015; 7(308): 308ra158.

11. Matos T.R., de Rie M.A., Teunissen M.B. Research techniques made simple: high-throughput sequencing of the T-cell receptor. J Invest Dermatol. 2017; 137(6): e131 - e138.

12. Scherer F., Kurtz D.M., Diehn M., Alizadeh A.A. High-throughput sequencing for noninvasivedisease detection in hematologic malignancies. Blood 2017; 130(4): 440 - 452.

13. Jawed S.I., Myskowski P.L., HorwitzS. et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and S zary syndrome): Part I. diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70(2): 205. e1 - 16.

14. Rea B., Haun P., EmersonR.et al. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. J Clin Pathol 2018; 71(9): 814 - 820.

15. Ferner R.E. Adverse drug reactions in dermatology. Clin Exp Dermatol. 2015; 40: 105 - 109.

16. Massimo Federico, Monica Bellei, Luigi Marchese et. al. Peripheral T cell lymphoma, not otherwise specified (PTCL NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018 Jun; 181(6): 760 - 769

17. Huang DY, Hu YF, Wei N, et. al. Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chin Med J (Engl). 2019 Feb 5; 132(3): 294 - 301

18. ELISEA. OLSEN. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy, Vol. 16, 2003, 311 - 321

19. Jared M. Campbell, - Emma Bateman, - Matthew D. Stephenson 1. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol. DOI 10.1007/s00280-016-3043-5

20. Mann, Johnson, Cohen et al. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. The Oncologist 2007; 12: 1247 - 1252

21. H Miles Prince, Youn H Kim, Steven M Horwitz, et. al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. www.thelancet.com Vol 390 August 5, 2017; 555 - 566

22. Onder Alpdogan, Saritha Kartan, William Johnson et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL). ChinClinOncol 2019; 8(1): 10

23. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375 - 2390.

24. Guitart J., Kennedy J., Ronan S. et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system tostandardize pathology reporting. J Cutan Pathol. 2001; 28(4): 174 - 183.

25. Raghavan S.S., Kim J. Histopathologic approach to epidermotropic lymphocytic infiltrates. Semin Cutan Med Surg 2018; 37: 56 - 60.

26. Charli-Joseph Y., Toussaint-Caire S., Lome-Maldonado C. et al. Approach to dermal-based lymphoid infiltrates and proliferations. Semin Cutan Med Surg 2018; 37: 61 - 74.

27. Kempf W., Mitteldorf C. Pathologic diagnosis of cutaneous lymphomas. Dermatol Clin. 2015; 33(4): 655 - 681.

28. Vandergriff T., Nezafati K.A., Susa J. et al. Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas. J Cutan Pathol. 2015; 42(5): 318 - 328.

29. Pimpinelli N., Olsen E.A., Santucci M. et al. Defining early mycosis fungoides. J AmAcad Dermatol. 2005; 53(6): 1053 - 1063.

30. Kash N., Massone C., Fink-Puches R., Cerroni L. Phenotypic variation in different lesions of mycosis fungoides biopsied within a short period of time from the same patient. Am J Dermatopathol. 2016; 38(7): 541 - 545.

31. de Masson A., Battistella M., Vignon-Pennamen M.D. et al. Syringotropic mycosis fungoides: clinical and histologic features, response to treatment, and outcome in 19 patients. J Am Acad Dermatol. 2014; 71(5): 926 - 934.

32. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. JAmAcadDermatol 2005; 53(6): 1053 - 63

33. Zhang Y, Wang Y, Yu R, etal. Molecular markers of early-stage mycosis fungoides. JInvestDermatol 2012; 132(6): 1698 - 706

34. Gerami P., Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007; 31(9): 1430 - 1438.

35. Haghighi B., Smoller B.R., LeBoit P.E. et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000; 13(5): 502 - 510.

36. Haththotuwa R, Zilinskiene L, Oliff J et. al. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and syndrome. BrJDermatol. 2017 Sep; 177(3): 877 - 878.

37. Salhany KE, Greer JP, Cousar JB, Collins RD. Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases.Am J Clin Pathol 1989; 92: 747 - 54

38. Kim E.J., Hess S., Richardson S.K. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005; 115(4): 798 - 812.

39. Zackheim H.S. Treatment of patch-stage mycosis fungoides with topical corticosteroids. DermatolTher. 2003; 16(4): 283 - 287

40. Diederen P.V., van Weelden H., Sanders C.J. et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am AcadDermatol. 2003; 48(2): 215 - 219.

41. Gathers R.C., Scherschun L., Malick F. et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am AcadDermatol. 2002; 47(2): 191 - 197.

42. Ponte P., V., Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J EurAcadDermatolVenereol. 2010; 24(6): 716 - 721.

43. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф., Воронцова А.А. Фототерапия грибовидного микоза. Онкогематология. 2019; 14(4): 39 - 47.

44. Querfeld C., Rosen S.T., Kuzel T.M. et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005; 141(3): 305 - 311.

45. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma. DermatolTher. 2003; 16(4): 311 - 321.

46. Zackheim H.S., Kashani-Sabet M., McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49(5): 873 - 878.

47. Prince H.M., Whittaker S., Hoppe R.T. How I treat mycosis fungoides and syndrome. Blood. 2009; 114: 4337 - 4353

48. Duvic M., Talpur R., Ni X. et al. Phase 2 trial of oral vorinostat (suberoylanilidehydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109(1): 31 - 39

49. Olsen E.A., Kim Y.H., Kuzel T.M. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(21): 3109 - 3115.

50. Duvic M., Olsen E.A., Breneman D. et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009; 9(6): 412 - 416.

51. Kim YH, Tavallaee M, Sundram U, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015; 10(33(32)): 3750 - 8.

52. Prince HM, Kim YH, Horwitz SM, al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 5(390(10094)): 555 - 566.

53. Hoppe R.T. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003; 16 (4): 347 - 354

54. Hymes K.B. Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park). 2007; 21(2 Suppl 1): 18 - 23.

55. Н.В. Ильин, Е.Н. Николаева, Ю.Н. Виноградова и соавт. Применение лучевой терапии электронным пучком в лечении первичных лимфом кожи. Применение лучевой терапии электронным пучком в лечении первичных лимфом кожи. 2009; 1. С. - 27 - 31

56. Чистякова И.А., Самсонов В.А., Потекаев Н.С. и соавт. Лучевая терапия больных T-клеточной лимфомой кожи. Вестн. Дерматол. Венерол. 2007; 6. С. - 34 - 36.

57. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002 - 6.

58. Franz Trautinger, Johanna Eder, Chalid Assaf, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment ofmycosis fungoides/Se'zary syndrome e Update 2017. European Journal of Cancer 77(2017) 57 - 74

59. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000 Jul; 18(13): 2603 - 6

60. Grozea PN, Jones SE, McKelvey EM., et al. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep. 1979 Apr; 63(4): 647 - 53

61. Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang et al. Bortezomib in combination with CHOP as first-line treatmentfor patients with stage III/IV peripheral T-cell lymphomas: Amulticentre, single-arm, phase 2 trial. European Journal of Cancer, 48(17), 3223 - 3231

62. Wu P.A., Kim Y.H., Lavori P.W. et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S zary syndrome. Biol Blood Marrow Transplant. 2009; 15(8): 982 - 990

63. Duarte R.F., Canals C., Onida F. et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28(29): 4492 - 4499

64. Serrano L., Martinez-Escala M.E., ZhouX.A., Guitart J. Pruritus in cutaneous T-cell lymphoma and its management.Dermatol Clin 2018; 36: 245 - 258] [Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564 - 568

65. Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. ActaDermVenereol. 2019; 99(5): 469 - 506

66. Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564 - 568

67. Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи: руководство для врачей. - М.: Практическая медицина, 2010. - 366 с.